Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523218 · ClinicalTrials.gov registry record · NA
A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory
A NA study of Cognitive Decline and Cognitive Function, sponsored by Scale Media.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06523218: Active NA study of Cognitive Decline and Cognitive Function, sponsored by Scale Media.
NCT06523218 is a NA study of Cognitive Decline and Cognitive Function that is active but no longer recruiting, run by Scale Media. The registered enrollment target is 50 participants, below the 1,149-participant average among 61 other Cognitive Decline trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06523218, a NA study of Cognitive Decline and Cognitive Function, is active but no longer recruiting, sponsored by Scale Media.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the test product or a placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT MindMD Supplement
Study Locations (1)
California
- Citruslabs - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2024-08-17 |
| Phase | NA |
What the registry record for NCT06523218 still lists
NCT06523218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,149-participant average among 61 other Cognitive Decline trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06523218 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06523218 about?
NCT06523218 is a clinical study titled "A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory". This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the te...
What is the current status of trial NCT06523218?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-05-17. Estimated completion is 2024-08-17.
What conditions does trial NCT06523218 study?
This clinical trial studies the following conditions: Cognitive Decline, Cognitive Function.
What interventions are being tested in trial NCT06523218?
The interventions under investigation include: Placebo (OTHER), MindMD Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06523218?
This trial is sponsored by Scale Media, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06523218 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06523218's enrollment target sits among peer trials
50 51st of 61 higher than 10 of 61 other Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)
RECRUITING · NA
-
Preventing Cognitive Decline by Reducing BP Target Trial
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Exercise Adherence and Cognitive Decline: Phase 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI